Lululab, an AI skin analysis solution company, announced on the 3rd that it has signed an exclusive domestic distribution agreement with medical and bio company L&C BIO for the AI 3D skin diagnosis solution “LuskinX.”

Under this agreement, Lululab plans to expand its precision skin diagnosis solution into the hospital and clinic market, leveraging L&C BIO’s domestic hospital and clinic network.

LuskinX is an AI 3D skin diagnosis solution that conducts multidimensional analysis of key skin indicators such as redness, pigmentation, pores, wrinkles, and acne through a combination of standard, polarized, and UV imaging. According to the company, it applies a deep learning algorithm trained on more than 5 million skin data records from about 60 countries, and provides not only an integrated score but also quantifies the depth, size, and number of each item. It is based on seven AI analysis technologies developed by Lululab and more than 35 related technical research papers.

Based on the diagnosis results, it also provides personalized treatment recommendations, predictive simulations, and pre- and post-treatment comparison reports, thereby supporting data-based decision-making during the consultation process.

Through this collaboration, Lululab will offer a data-driven consultation environment linked to key treatment solutions, including L&C BIO’s flagship product “Lituo.”

Choi Yong-joon, CEO of Lululab, said, “AI skin diagnosis has now established itself as core infrastructure that supports medical decision-making, going beyond a simple auxiliary tool,” adding, “This collaboration is significant in that it presents an integrated beauty and medical AI platform model that connects ‘diagnosis–recommendation–treatment–result comparison.’”

He continued, “Together with L&C BIO, we will expand a data-based precision treatment environment in the domestic medical market and further strengthen the competitiveness of K-beauty tech in the global market.”

Popular News